[{"id":"db9b5ab2-cce0-4f94-8479-294ddf816572","acronym":"","url":"https://clinicaltrials.gov/study/NCT01892527","created_at":"2021-01-18T08:30:02.263Z","updated_at":"2024-07-02T16:36:04.195Z","phase":"Phase 2","brief_title":"Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects","source_id_and_acronym":"NCT01892527","lead_sponsor":"Armando Santoro, MD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab) • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2022-09-09"},{"id":"0f5d27ed-ec3b-4909-96cf-5081f55172f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01075048","created_at":"2021-01-18T04:14:08.252Z","updated_at":"2024-07-02T16:36:32.246Z","phase":"Phase 1/2","brief_title":"ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01075048","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 01/26/2010","start_date":" 01/26/2010","primary_txt":" Primary completion: 10/12/2012","primary_completion_date":" 10/12/2012","study_txt":" Completion: 02/20/2015","study_completion_date":" 02/20/2015","last_update_posted":"2021-04-08"},{"id":"e24fe967-71a4-411d-8e88-e2c4b7a0ed50","acronym":"","url":"https://clinicaltrials.gov/study/NCT02049060","created_at":"2021-01-22T23:52:33.713Z","updated_at":"2024-07-02T16:36:35.705Z","phase":"Phase 1/2","brief_title":"Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin","source_id_and_acronym":"NCT02049060","lead_sponsor":"Armando Santoro, MD","biomarkers":" MET • HGF","pipe":" | ","alterations":" MET expression","tags":["MET • HGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2021-01-22"},{"id":"18a3a23b-fff3-4d88-99d5-0e92fad6723c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01447914","created_at":"2021-01-29T07:02:21.851Z","updated_at":"2024-07-02T16:36:56.164Z","phase":"Phase 2","brief_title":"Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma","source_id_and_acronym":"NCT01447914","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2019-08-28"},{"id":"b36864cd-734d-4135-a98f-0ae696eb70c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01696955","created_at":"2021-01-18T07:22:25.864Z","updated_at":"2024-07-02T16:37:04.509Z","phase":"Phase 2","brief_title":"Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01696955","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MET","pipe":" | ","alterations":" MET expression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 08/20/2012","start_date":" 08/20/2012","primary_txt":" Primary completion: 05/05/2017","primary_completion_date":" 05/05/2017","study_txt":" Completion: 05/05/2017","study_completion_date":" 05/05/2017","last_update_posted":"2018-12-19"},{"id":"8c95c0fe-f0c5-418f-a301-d0d19233b005","acronym":"","url":"https://clinicaltrials.gov/study/NCT01395758","created_at":"2021-01-18T05:43:59.926Z","updated_at":"2024-07-02T16:37:11.859Z","phase":"Phase 2","brief_title":"Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01395758","lead_sponsor":"ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck \u0026 Co., Inc.)","biomarkers":" KRAS • MET","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • docetaxel • pemetrexed • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2018-04-03"},{"id":"0214d5af-0cfe-4ce0-8f49-2e63e81209fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01749384","created_at":"2021-01-18T07:40:25.968Z","updated_at":"2024-07-02T16:37:17.150Z","phase":"Phase 1","brief_title":"Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01749384","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2012","start_date":" 12/06/2012","primary_txt":" Primary completion: 05/24/2016","primary_completion_date":" 05/24/2016","study_txt":" Completion: 05/24/2016","study_completion_date":" 05/24/2016","last_update_posted":"2017-10-12"},{"id":"8cf717b4-4e12-47ef-a4a5-e6aa2eeff806","acronym":"","url":"https://clinicaltrials.gov/study/NCT02029157","created_at":"2021-01-18T09:17:58.068Z","updated_at":"2024-07-02T16:37:17.245Z","phase":"Phase 3","brief_title":"A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT02029157","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET-H","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 386","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2017-10-09"},{"id":"1a21ad52-8c40-4853-8217-a4c0e52e32c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01069757","created_at":"2021-01-18T04:12:57.318Z","updated_at":"2024-07-02T16:37:24.388Z","phase":"Phase 1","brief_title":"A Study of ARQ 197 in Combination With Erlotinib","source_id_and_acronym":"NCT01069757","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2017-03-15"},{"id":"bf360333-49e1-4228-a880-2991928bd419","acronym":"","url":"https://clinicaltrials.gov/study/NCT01251796","created_at":"2021-01-18T05:02:41.745Z","updated_at":"2024-07-02T16:37:24.384Z","phase":"Phase 1","brief_title":"A Study of ARQ 197 in Combination With Erlotinib","source_id_and_acronym":"NCT01251796","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/01/2012","study_completion_date":" 11/01/2012","last_update_posted":"2017-03-15"}]